In this issue:
Cost-effectiveness of 5-ASA plus biologics
Trifluridine/tipiracil + ramucirumab for previously treated advanced gastric cancer
Chronic opioid use and biologic discontinuation in IBD
Ustekinumab or vedolizumab in pregnant IBD patients
Immune checkpoint inhibitors in patients with pre-existing IBD
Dermatological reactions in IBD treated with anti-TNF therapy
Early vedolizumab and longer-term surgery rates in CD
Vedolizumab vs adalimumab in CD
Drug survival of anti-TNF agents vs vedolizumab
Cumulative exposure to infliximab and rate of infection
Please login below to download this issue (PDF)